Marzia Perluigi

List of Publications by Year
in descending order

92	6,581	61984	64796
papers	citations	43 h-index	79 g-index

96	96	96	7573
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oxidative stress and mTOR in Down syndrome brain: Link to Alzheimer's dysmetabolism, neuropathology, and possible therapies. , 2022, , 75-96.		0
2	Aberrant crosstalk between insulin signaling and mTOR in young Down syndrome individuals revealed by neuronalâ€derived extracellular vesicles. Alzheimer's and Dementia, 2022, 18, 1498-1510.	0.8	16
3	Aberrant protein networks in Alzheimer disease. Nature Reviews Neurology, 2022, 18, 255-256.	10.1	5
4	CAPE and its synthetic derivative VP961 restore BACH1/NRF2 axis in Down Syndrome. Free Radical Biology and Medicine, 2022, 183, 1-13.	2.9	9
5	Role of Biliverdin Reductase A in the Regulation of Insulin Signaling in Metabolic and Neurodegenerative Diseases: An Update. International Journal of Molecular Sciences, 2022, 23, 5574.	4.1	4
6	Chronic PERK induction promotes Alzheimer-like neuropathology in Down syndrome: Insights for therapeutic intervention. Progress in Neurobiology, 2021, 196, 101892.	5.7	21
7	The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome. Neurotherapeutics, 2021, 18, 340-363.	4.4	12
8	Polyubiquitin Profile in Down Syndrome and Alzheimerâ€™s Disease Brain. Methods in Molecular Biology, 2021, 2261, 79-91.	0.9	1
9	Insulin resistance, oxidative stress and mitochondrial defects in Ts65dn mice brain: A harmful synergistic path in down syndrome. Free Radical Biology and Medicine, 2021, 165, 152-170.	2.9	26
10	High-Fat Diet Leads to Reduced Protein O-GlcNAcylation and Mitochondrial Defects Promoting the Development of Alzheimerâ€™s Disease Signatures. International Journal of Molecular Sciences, 2021, 22, 3746.	4.1	17
11	The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radical Biology and Medicine, 2021, 176, 16-33.	2.9	53
12	Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society. Molecular Syndromology, 2021, 12, 202-218.	0.8	6
13	Protein Oxidative Damage in UV-Related Skin Cancer and Dysplastic Lesions Contributes to Neoplastic Promotion and Progression. Cancers, 2020, 12, 110.	3.7	8
14	Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions. Frontiers in Neuroscience, 2020, 14, 670.	2.8	48
15	Proteomics Study of Peripheral Blood Mononuclear Cells in Down Syndrome Children. Antioxidants, 2020, 9, 1112.	5.1	5
16	BVR-A Deficiency Leads to Autophagy Impairment through the Dysregulation of AMPK/mTOR Axis in the Brainâ€”Implications for Neurodegeneration. Antioxidants, 2020, 9, 671.	5.1	17
17	The BACH1/Nrf2 Axis in Brain in Down Syndrome and Transition to Alzheimer Disease-Like Neuropathology and Dementia. Antioxidants, 2020, 9, 779.	5.1	21
18	The Anti-Diabetic Drug Metformin Rescues Aberrant Mitochondrial Activity and Restrains Oxidative Stress in a Female Mouse Model of Rett Syndrome. Journal of Clinical Medicine, 2020, 9, 1669.	2.4	17

#	Article	IF	Citations
19	Multiple Herpes Simplex Virus-1 (HSV-1) Reactivations Induce Protein Oxidative Damage in Mouse Brain: Novel Mechanisms for Alzheimerâ€™s Disease Progression. Microorganisms, 2020, 8, 972.	3.6	17
20	Brain insulin resistance triggers early onset Alzheimer disease in Down syndrome. Neurobiology of Disease, 2020, 137, 104772.	4.4	54
21	Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease. Molecular Neurobiology, 2019, 56, 2922-2943.	4.0	70
22	Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives. CNS Drugs, 2019, 33, 957-969.	5.9	45
23	Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1490-1501.	3.8	29
24	Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome. Redox Biology, 2019, 23, 101162.	9.0	46
25	Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease. Neurobiology of Disease, 2019, 125, 176-189.	4.4	55
26	Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models. Journal of Alzheimer's Disease, 2018, 62, 347-359.	2.6	19
27	Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism. Free Radical Biology and Medicine, 2018, 114, 84-93.	2.9	38
28	Down syndrome: From development to adult life to Alzheimer disease. Free Radical Biology and Medicine, 2018, 114, 1-2.	2.9	6
29	mTOR in Down syndrome: Role in AÃŸ and tau neuropathology and transition to Alzheimer disease-like dementia. Free Radical Biology and Medicine, 2018, 114, 94-101.	2.9	72
30	Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome. Translational Neurodegeneration, 2018, 7, 28.	8.0	76
31	Biliverdin reductase-A impairment links brain insulin resistance with increased AÎ² production in an animal model of aging: Implications for Alzheimer disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3181-3194.	3.8	49
32	Poly-ubiquitin profile in Alzheimer disease brain. Neurobiology of Disease, 2018, 118, 129-141.	4.4	29
33	Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3309-3321.	3.8	29
34	HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology. Free Radical Biology and Medicine, 2017, 111, 262-269.	2.9	41
35	The Triangle of Death in Alzheimer's Disease Brain: The Aberrant Cross-Talk Among Energy Metabolism, Mammalian Target of Rapamycin Signaling, and Protein Homeostasis Revealed by Redox Proteomics. Antioxidants and Redox Signaling, 2017, 26, 364-387.	5.4	97
36	Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology. Antioxidants and Redox Signaling, 2017, 26, 280-298.	5.4	38

#	Article	IF	Citations
37	[P3â€“160]: ABERRANT POLYUBIQUITOME PROFILE IN DOWN SYNDROME AND ALZHEIMER DISEASE BRAIN. Alzheimer's and Dementia, 2017, 13, P995.	0.8	0
38	[O2â€“02â€“04]: ALTERED PROTEIN Oâ€GLCNACYLATION PROFILE REVEALED BY PROTEOMICS: NOVEL INSIGHTS ON PROTEIN SIGNALING MECHANISMS IN ALZHEIMER DISEASE. Alzheimer's and Dementia, 2017, 13, P553.	0.8	0
39	It Is All about (U)biquitin: Role of Altered Ubiquitin-Proteasome System and UCHL1 in Alzheimer Disease. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-12.	4.0	88
40	Cathepsin D as a therapeutic target in Alzheimerâ€™s disease. Expert Opinion on Therapeutic Targets, 2016, 20, 1393-1395.	3.4	41
41	Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype. Journal of Alzheimer's Disease, 2016, 52, 359-371.	2.6	35
42	Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: A new paradigm. Free Radical Biology and Medicine, 2016, 91, 127-142.	2.9	98
43	Increased Mammalian Target of Rapamycin Signaling Contributes to the Accumulation of Protein Oxidative Damage in a Mouse Model of Down's Syndrome. Neurodegenerative Diseases, 2016, 16, 62-68.	1.4	35
44	Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients. Free Radical Biology and Medicine, 2016, 91, 1-9.	2.9	74
45	Redox Proteomics in Human Biofluids: Sample Preparation, Separation and Immunochemical Tagging for Analysis of Protein Oxidation. Methods in Molecular Biology, 2016, 1303, 391-403.	0.9	7
46	Basal brain oxidative and nitrative stress levels are finely regulated by the interplay between superoxide dismutase 2 and p53. Journal of Neuroscience Research, 2015, 93, 1728-1739.	2.9	18
47	Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with preâ€clinical AD, amnestic mild cognitive impairment and lateâ€stage AD. Journal of Neurochemistry, 2015, 133, 739-749.	3.9	276
48	Bach1 Overexpression in Down Syndrome Correlates with the Alteration of the HO-1/BVR-A System: Insights for Transition to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 1107-1120.	2.6	53
49	Age-related changes in the proteostasis network in the brain of the naked mole-rat: Implications promoting healthy longevity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2213-2224.	3.8	47
50	mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiology of Disease, 2015, 84, 39-49.	4.4	261
51	Oxidative Stress and Proteostasis Network: Culprit and Casualty of Alzheimerâ€™s-Like Neurodegeneration. Advances in Geriatrics, 2014, 2014, 1-14.	1.6	36
52	Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: Insights from proteomics. Proteomics - Clinical Applications, 2014, 8, 73-85.	1.6	52
53	Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Free Radical Biology and Medicine, 2014, 71, 270-280.	2.9	87
54	Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. Biochemical Journal, 2014, 463, 177-189.	3.7	93

#	Article	IF	Citations
55	An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. Free Radical Biology and Medicine, 2014, 76, 89-95.	2.9	23
56	Redox proteomics and the dynamic molecular landscape of the aging brain. Ageing Research Reviews, 2014, 13, 75-89.	10.9	56
57	Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1144-1153.	3.8	127
58	Down Syndrome as a Special Case of Oxidatively Induced Developmental Dysregulation. Oxidative Stress in Applied Basic Research and Clinical Practice, 2014, , 127-142.	0.4	0
59	Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: Redox proteomics analysis of human brain. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1249-1259.	3.8	109
60	Proteomics strategies to analyze HPV-transformed cells: relevance to cervical cancer. Expert Review of Proteomics, 2013, 10, 461-472.	3.0	12
61	Lipid peroxidation triggers neurodegeneration: A redox proteomics view into the Alzheimer disease brain. Free Radical Biology and Medicine, 2013, 62, 157-169.	2.9	365
62	Involvement of Oxidative Stress in Occurrence of Relapses in Multiple Sclerosis: The Spectrum of Oxidatively Modified Serum Proteins Detected by Proteomics and Redox Proteomics Analysis. PLoS ONE, 2013, 8, e65184.	2.5	73
63	Biliverdin Reductase-A correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain. Neural Regeneration Research, 2013, 8, 1925-37.	3.0	11
64	Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia. Current Gerontology and Geriatrics Research, 2012, 2012, 1-10.	1.6	139
65	4-Hydroxy-2-Nonenal, a Reactive Product of Lipid Peroxidation, and Neurodegenerative Diseases: A Toxic Combination Illuminated by Redox Proteomics Studies. Antioxidants and Redox Signaling, 2012, 17, 1590-1609.	5.4	184
66	HO-1/BVR-A System Analysis in Plasma from Probable Alzheimer's Disease and Mild Cognitive Impairment Subjects: A Potential Biochemical Marker for the Prediction of the Disease. Journal of Alzheimer's Disease, 2012, 32, 277-289.	2.6	43
67	Lack of p53 Decreases Basal Oxidative Stress Levels in the Brain Through Upregulation of Thioredoxin-1, Biliverdin Reductase-A, Manganese Superoxide Dismutase, and Nuclear Factor Kappa-B. Antioxidants and Redox Signaling, 2012, 16, 1407-1420.	5.4	30
68	Inhibition of lipid peroxidation and protein oxidation by endogenous and exogenous antioxidants in rat brain microsomes in vitro. Neuroscience Letters, 2012, 518, 101-105.	2.1	72
69	Redox Proteomics in Selected Neurodegenerative Disorders: From Its Infancy to Future Applications. Antioxidants and Redox Signaling, 2012, 17, 1610-1655.	5.4	152
70	Redox Proteomics Analyses of the Influence of Co-Expression of Wild-Type or Mutated LRRK2 and Tau on C. elegans Protein Expression and Oxidative Modification: Relevance to Parkinson Disease. Antioxidants and Redox Signaling, 2012, 17, 1490-1506.	5.4	43
71	Oxidative Stress in HPV-Driven Viral Carcinogenesis: Redox Proteomics Analysis of HPV-16 Dysplastic and Neoplastic Tissues. PLoS ONE, 2012, 7, e34366.	2.5	63
72	Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radical Biology and Medicine, 2012, 52, 2292-2301.	2.9	108

#	Article	IF	Citations
73	The identification of protein biomarkers for oxidative stress in Down syndrome. Expert Review of Proteomics, 2011, 8, 427-429.	3.0	26
74	Biliverdin reductase-A protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 480-487.	3.8	77
75	Circulating biomarkers of protein oxidation for Alzheimer disease: Expectations within limits. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 1785-1795.	2.3	56
76	Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid. Proteomics - Clinical Applications, 2011, 5, 167-178.	1.6	86
77	Oxidative and Nitrosative Modifications of Biliverdin Reductase-A in the Brain of Subjects with Alzheimer's Disease and Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2011, 25, 623-633.	2.6	85
78	Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: An investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Research, 2010, 1333, 72-81.	2.2	94
79	The wheat germ agglutininâ€fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: Implications for disease pathogenesis and progression. Journal of Neuroscience Research, 2010, 88, 3566-3577.	2.9	34
80	Redox Proteomic Analysis of Carbonylated Brain Proteins in Mild Cognitive Impairment and Early Alzheimer's Disease. Antioxidants and Redox Signaling, 2010, 12, 327-336.	5.4	108
81	Proteomics analysis of protein expression and specific protein oxidation in human papillomavirus transformed keratinocytes upon UVB irradiation. Journal of Cellular and Molecular Medicine, 2009, 13, 1809-1822.	3.6	23
82	Oxidatively modified proteins in Alzheimerâ€™s disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathologica, 2009, 118, 131-150.	7.7	194
83	Redox proteomics identification of 4â€hydroxynonenalâ€modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics - Clinical Applications, 2009, 3, 682-693.	1.6	172
84	Redox proteomic identification of 4-Hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiology of Disease, 2008, 30, 107-120.	4.4	236
85	Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: Implications for the role of nitration in the progression of Alzheimer's disease. Brain Research, 2007, 1148, 243-248.	2.2	211
86	Protein Oxidation and Lipid Peroxidation in Brain of Subjects with Alzheimer's Disease: Insights into Mechanism of Neurodegeneration from Redox Proteomics. Antioxidants and Redox Signaling, 2006, 8, 2021-2037.	5.4	224
87	Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neuroscience Letters, 2006, 397, 170-173.	2.1	227
88	Oxidative stress in Alzheimer's disease brain: New insights from redox proteomics. European Journal of Pharmacology, 2006, 545, 39-50.	3.5	316
89	Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice-A model of familial amyotrophic lateral sclerosis. Free Radical Biology and Medicine, 2005, 38, 960-968.	2.9	141
90	In vivo protection of synaptosomes from oxidative stress mediated by Fe2+/H2O2 or 2,2-azobis-(2-amidinopropane) dihydrochloride by the glutathione mimetic tricyclodecan-9-yl-xanthogenate. Free Radical Biology and Medicine, 2005, 38, 1023-1031.	2.9	42

#	Article	IF	Citations
91	Proteomic Analysis of Protein Expression and Oxidative Modification in R6/2 Transgenic Mice. Molecular and Cellular Proteomics, 2005, 4, 1849-1861.	3.8	156
92	Tyrosinase protects human melanocytes from ROS-generating compounds. Biochemical and Biophysical Research Communications, 2003, 305, 250-256.	2.1	66